Nucleus Biotech
BiotechSeries DRisk Assessment
Nucleus Biotech shows no distress signals across available dimensions. However, limited Glassdoor and media coverage reduces monitoring confidence. Stable headcount with one open role suggests normal operations.
Signal Dimensions
Peak HC
51
Current HC
51
HC Decline
0%
Open Roles
1
Stable headcount with active hiring. No workforce concerns.
Last Filing
Mar 2026
Auditor Changes
0
Director Changes
0
Overdue Filings
0
Filings current. Clean record.
Last Raise
Series D
Time Since Raise
4 months
Funding Stage
Late Growth
Burn Indicator
Low
Very recent Series D. Strong capitalisation.
Competitor Raises
0
SoV Trend
N/A
Talent Outflow
Low
Sector Growth
8%
No competitive pressure detected.
No Glassdoor presence detected. Common for pre-Series B or highly technical companies. Weight shifted to workforce and funding signals.
Low media signal — not in active news cycle. Typical of early-stage or low-scrutiny assets. Absence of coverage is not absence of risk.
Score Drivers
No risk drivers detected. All signals within healthy parameters.
Confidence: LOW · 4 of 6 signals active
Recommended Actions
Routine monitoring recommended. No escalation required.